Fresenius Agrees to Massachusetts MDL for GranuFlo and NaturaLyte Lawsuits
Fresenius, the manufacturer of dialysis products GranuFlo and NaturaLyte, has recently agreed to consolidate pretrial proceedings of numerous lawsuits filed in several Federal District Courts to the Federal District Court of Massachusetts. Fresenius faces hundreds to potentially thousands of lawsuits from dialysis patients who claim to have suffered serious injuries including heart attack, stroke, and death from using GranuFlo or NaturaLyte.
GranuFlo and NaturaLyte are two products used in dialysis treatment for patients who suffer from end-stage renal disease. These products were the subject of a Class I recall by the FDA in early 2012 due to serious health risks. Fresenius conducted its own private study of the effects of GranuFlo and NaturaLyte in dialysis patients at a number of its clinics in 2010. During that time, 941 patients suffered cardiopulmonary arrests due to high serum bicarbonate levels. The company issued an internal memo to its facilities after the study cautioning health care professionals regarding the use of these products. The company did not provide this warning to outside clinics, hospitals, or patients.
If you or someone you care about is a dialysis patient who has suffered an injury such as stroke, heart attack, or death—contact us. Our product liability attorneys can advise you of your legal rights and options regarding compensation for your injuries.
